CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's senior management team will deliver a presentation on March 3, 2025, at 10:30 a.m. ET.
Investors and interested parties can access a live webcast of the fireside chat through the company's website under the 'Events & Presentations' section. The presentation recording will remain available for replay on the company's website for 14 days following the event.
CRISPR Therapeutics (NASDAQ: CRSP), una compagnia biofarmaceutica specializzata in medicinali basati sui geni, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Il team di gestione senior dell'azienda presenterà il proprio intervento il 3 marzo 2025, alle 10:30 a.m. ET.
Gli investitori e le parti interessate possono accedere a una diretta streaming del colloquio attraverso il sito web dell'azienda nella sezione 'Eventi e Presentazioni'. La registrazione della presentazione rimarrà disponibile per la visione on-demand sul sito web dell'azienda per 14 giorni dopo l'evento.
CRISPR Therapeutics (NASDAQ: CRSP), una empresa biofarmacéutica especializada en medicamentos basados en genes, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. El equipo de alta dirección de la empresa realizará una presentación el 3 de marzo de 2025, a las 10:30 a.m. ET.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la charla a través del sitio web de la empresa en la sección 'Eventos y Presentaciones'. La grabación de la presentación estará disponible para su reproducción en el sitio web de la empresa durante 14 días después del evento.
CRISPR Therapeutics (NASDAQ: CRSP), 유전자 기반 의약품을 전문으로 하는 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다. 회사의 고위 경영진 팀은 2025년 3월 3일 오전 10시 30분 ET에 발표를 진행할 예정입니다.
투자자 및 관심 있는 당사자는 회사 웹사이트의 '이벤트 및 발표' 섹션을 통해 화상 회의의 생중계를 접속할 수 있습니다. 발표 녹화는 행사 후 14일 동안 회사 웹사이트에서 재생할 수 있습니다.
CRISPR Therapeutics (NASDAQ: CRSP), une entreprise biopharmaceutique spécialisée dans les médicaments basés sur les gènes, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. L'équipe de direction senior de l'entreprise fera une présentation le 3 mars 2025 à 10h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la discussion via le site web de l'entreprise dans la section 'Événements et Présentations'. L'enregistrement de la présentation sera disponible en replay sur le site web de l'entreprise pendant 14 jours après l'événement.
CRISPR Therapeutics (NASDAQ: CRSP), ein biopharmazeutisches Unternehmen, das auf genbasierte Medikamente spezialisiert ist, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Das Management-Team des Unternehmens wird am 3. März 2025 um 10:30 Uhr ET eine Präsentation halten.
Investoren und Interessierte können über die Website des Unternehmens im Abschnitt 'Veranstaltungen & Präsentationen' auf einen Live-Stream des Gesprächs zugreifen. Die Aufnahme der Präsentation wird für 14 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the TD Cowen Healthcare Conference 2025?
How long will CRSP's TD Cowen Conference presentation be available for replay?
Where can investors watch CRSP's TD Cowen Conference presentation?
What type of presentation will CRSP deliver at the TD Cowen Healthcare Conference?
